Literature DB >> 19450762

Donor CMV serostatus not predictive of relapse in D-/R- pediatric HCT.

Giovanna Travi, Steven A Pergam, Hu Xie, Michael J Boeckh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19450762      PMCID： PMC2699379          DOI： 10.1016/j.bbmt.2009.03.025

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  6 in total

1.  Management of CMV infections: recommendations from the infectious diseases working party of the EBMT.

Authors:  P Ljungman; P Reusser; R de la Camara; H Einsele; D Engelhard; P Ribaud; K Ward
Journal:  Bone Marrow Transplant       Date:  2004-06       Impact factor: 5.483

Review 2.  Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies.

Authors:  Michael Boeckh; W Garrett Nichols; Genovefa Papanicolaou; Robert Rubin; John R Wingard; John Zaia
Journal:  Biol Blood Marrow Transplant       Date:  2003-09       Impact factor: 5.742

3.  Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy.

Authors:  Carolyn E Behrendt; Joseph Rosenthal; Ellen Bolotin; Ryotaro Nakamura; John Zaia; Stephen J Forman
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

Review 4.  Acute lymphoblastic leukemia in infancy.

Authors:  Lewis B Silverman
Journal:  Pediatr Blood Cancer       Date:  2007-12       Impact factor: 3.167

5.  One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation.

Authors:  Veronique Erard; Katherine A Guthrie; Cara Varley; Judson Heugel; Anna Wald; Mary E D Flowers; Lawrence Corey; Michael Boeckh
Journal:  Blood       Date:  2007-05-21       Impact factor: 22.113

Review 6.  The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy.

Authors:  Michael Boeckh; W Garrett Nichols
Journal:  Blood       Date:  2003-11-26       Impact factor: 22.113
  6 in total
  5 in total

1.  Not just leukemia: CMV may protect against lymphoma recurrence after allogeneic transplant.

Authors:  Jonathan U Peled; Robert R Jenq
Journal:  Leuk Lymphoma       Date:  2016-10-12

2.  Institution affects association between CMV seronegative graft and leukemic relapse after pediatric HCT.

Authors:  Carolyn E Behrendt; Ryotaro Nakamura; John Zaia
Journal:  Biol Blood Marrow Transplant       Date:  2009-08-03       Impact factor: 5.742

3.  Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis.

Authors:  Pierre Teira; Minoo Battiwalla; Muthalagu Ramanathan; A John Barrett; Kwang Woo Ahn; Min Chen; Jaime S Green; Ayman Saad; Joseph H Antin; Bipin N Savani; Hillard M Lazarus; Matthew Seftel; Wael Saber; David Marks; Mahmoud Aljurf; Maxim Norkin; John R Wingard; Caroline A Lindemans; Michael Boeckh; Marcie L Riches; Jeffery J Auletta
Journal:  Blood       Date:  2016-02-16       Impact factor: 22.113

4.  Impact of early CMV reactivation in cord blood stem cell recipients in the current era.

Authors:  M Ramanathan; P Teira; M Battiwalla; J Barrett; K W Ahn; M Chen; J Green; M Laughlin; H M Lazarus; D Marks; A Saad; M Seftel; W Saber; B Savani; E K Waller; J Wingard; J J Auletta; C A Lindemans; M Boeckh; M L Riches
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

Review 5.  Cytomegalovirus Infections in Children with Primary and Secondary Immune Deficiencies.

Authors:  Caroline M Bateman; Alison Kesson; Madeleine Powys; Melanie Wong; Emily Blyth
Journal:  Viruses       Date:  2021-10-05       Impact factor: 5.048
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.